Compare Elastic NV (ESTC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Regeneron Pharmaceuticals Inc — how do they compare? Elastic NV trades at $75.38 (market cap $7.94B), while Regeneron Pharmaceuticals Inc trades at $788 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 10.3× Elastic NV's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Elastic NV pays none. Which is the better fit depends on your goals.
| ESTC | REGN | |
|---|---|---|
Market Cap | $7.94B | $82.06B |
Sector | Technology | Health |
52-Week High | $94.47 | $812.27 |
52-Week Low | $43.30 | $555.51 |
Enterprise Value | $7.16B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
